Title:
ANTIBODY-MULTIDRUG CONJUGATE
Document Type and Number:
WIPO Patent Application WO/2023/234426
Kind Code:
A1
Abstract:
Provided is a more useful antitumor drug that is the result of further advancing conventional antibody-drug conjugates. An antibody-multidrug conjugate represented by general formula (I): [in the formula, the symbols have the meanings set forth in the description of the present application] or a pharmacologically acceptable salt thereof.
Inventors:
TSUZAKI YASUNORI (JP)
MIZUNO GEN (JP)
KASHIWAGI TAKAMASA (JP)
TANAKA MASAYUKI (JP)
SHIMIZU HAYATO (JP)
AGA YASUHIRO (JP)
NONOUCHI SHINPEI (JP)
TOKUNAGA YASUNORI (JP)
MATSUSHITA TAKASHI (JP)
KIMURA TOMIO (JP)
MIZUNO GEN (JP)
KASHIWAGI TAKAMASA (JP)
TANAKA MASAYUKI (JP)
SHIMIZU HAYATO (JP)
AGA YASUHIRO (JP)
NONOUCHI SHINPEI (JP)
TOKUNAGA YASUNORI (JP)
MATSUSHITA TAKASHI (JP)
KIMURA TOMIO (JP)
Application Number:
PCT/JP2023/021637
Publication Date:
December 07, 2023
Filing Date:
June 02, 2023
Export Citation:
Assignee:
UBE CORP (JP)
International Classes:
A61K47/68; A61K31/337; A61K31/357; A61K31/407; A61K31/4375; A61K31/4745; A61K31/475; A61K31/537; A61K31/5513; A61K31/675; A61K31/7034; A61K31/706; A61K38/07; A61K39/395; A61K45/00; A61P35/00; C07K16/28
Domestic Patent References:
| WO2014061277A1 | 2014-04-24 | |||
| WO2020236817A2 | 2020-11-26 | |||
| WO2022115451A1 | 2022-06-02 |
Foreign References:
| JP2013136590A | 2013-07-11 |
Other References:
XIAO, DIAN ET AL.: "A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate", THERANOSTICS, vol. 11, no. 6, 2021, pages 2550 - 2563, XP093087170, DOI: 10.7150/thno.51232
SU, ZHENG ET AL.: "Antibody-drug conjugates: Recent advances in linker chemistry", ACTA PHARMACEUTICA SINICA B, vol. 11, no. 12, 2021, pages 3889 - 3907, XP093087740, DOI: 10.1016/j.apsb.2021.03.042
LIU, LIANQI ET AL.: "Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates", DRUG DELIVERY, vol. 28, no. 1, 2021, pages 2603 - 2617, XP093087176, DOI: 10.1080/10717544.2021.2008053
LAU, ULAND Y. ET AL.: "Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins", MOL. PHARMACEUTICS, vol. 15, no. 9, 2018, pages 4063 - 4072, XP055618626, DOI: 10.1021/acs.molpharmaceut.8b00477
MANABE, SHINO: "Development and Current Status of Antibody-drug conjugate (ADC", DRUG DELIVERY SYSTEM, vol. 34, no. 1, 2019, pages 10 - 21, XP093087000
KERN, C. J. ET AL.: "Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs", BIOCONJUGATE CHEM ., vol. 27, no. 9, 2016, pages 2081 - 2088, XP055557206, DOI: 10.1021/acs.bioconjchem.6b00337
SU, ZHENG ET AL.: "Antibody-drug conjugates: Recent advances in linker chemistry", ACTA PHARMACEUTICA SINICA B, vol. 11, no. 12, 2021, pages 3889 - 3907, XP093087740, DOI: 10.1016/j.apsb.2021.03.042
LIU, LIANQI ET AL.: "Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates", DRUG DELIVERY, vol. 28, no. 1, 2021, pages 2603 - 2617, XP093087176, DOI: 10.1080/10717544.2021.2008053
LAU, ULAND Y. ET AL.: "Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins", MOL. PHARMACEUTICS, vol. 15, no. 9, 2018, pages 4063 - 4072, XP055618626, DOI: 10.1021/acs.molpharmaceut.8b00477
MANABE, SHINO: "Development and Current Status of Antibody-drug conjugate (ADC", DRUG DELIVERY SYSTEM, vol. 34, no. 1, 2019, pages 10 - 21, XP093087000
KERN, C. J. ET AL.: "Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs", BIOCONJUGATE CHEM ., vol. 27, no. 9, 2016, pages 2081 - 2088, XP055557206, DOI: 10.1021/acs.bioconjchem.6b00337
Attorney, Agent or Firm:
TSUDA Osamu et al. (JP)
Download PDF:
Previous Patent: AMINO ACID ACTIVE ESTER AND SALT THEREOF
Next Patent: ANTIBODY-MULTIDRUG CONJUGATE PRECURSOR AND SYNTHETIC INTERMEDIATE THEREOF
Next Patent: ANTIBODY-MULTIDRUG CONJUGATE PRECURSOR AND SYNTHETIC INTERMEDIATE THEREOF